When stocks started trading on Friday, it marked a debut in the public markets for a company founded out of Johns Hopkins research that maintains an office in Baltimore.

Graybug Vision, now listed on the NASDAQ as GRAY, expects to raise $90 million in the initial public offering. The company said it went public with an “upsized” public offering, with shares at $16.

Founded in 2011, the Redwood City, California-based biopharmaceutical company is developing treatments for eye diseases that cause blindness. It expects to use the proceeds from the IPO to fund clinical trials for separate drugs it is developing to treat age-related macular degeneration and glaucoma, respectively.

READ FULL ARTICLE HERE